SyntheticMR Management

Management Kriterienprüfungen 4/4

SyntheticMR's CEO ist Ulrik Harrysson, ernannt in Jul 2019, hat eine Amtszeit von 4.75 Jahren. Die jährliche Gesamtvergütung beträgt SEK2.28M, bestehend aus 68.9% Gehalt und 31.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.34% der Aktien des Unternehmens, im Wert von SEK3.88M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.8 Jahre bzw. 3.9 Jahre.

Wichtige Informationen

Ulrik Harrysson

Geschäftsführender

SEK 2.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	68.9%
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	4.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.9yrs

Jüngste Management Updates

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ulrik Harrysson im Vergleich zu den Einnahmen von SyntheticMR verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	SEK 2m	SEK 2m	SEK 10m
Sep 30 2023	n/a	n/a	SEK 6m
Jun 30 2023	n/a	n/a	SEK 6m
Mar 31 2023	n/a	n/a	SEK 7m
Dec 31 2022	SEK 2m	SEK 2m	SEK 6m
Sep 30 2022	n/a	n/a	SEK 8m
Jun 30 2022	n/a	n/a	SEK 7m
Mar 31 2022	n/a	n/a	SEK 2m
Dec 31 2021	SEK 2m	SEK 2m	SEK 8m
Sep 30 2021	n/a	n/a	SEK 8m
Jun 30 2021	n/a	n/a	SEK 5m
Mar 31 2021	n/a	n/a	SEK 3m
Dec 31 2020	SEK 2m	SEK 1m	SEK 663k
Sep 30 2020	n/a	n/a	-SEK 6m
Jun 30 2020	n/a	n/a	-SEK 3m
Mar 31 2020	n/a	n/a	SEK 2m
Dec 31 2019	SEK 2m	SEK 822k	SEK 4m

Vergütung im Vergleich zum Markt: UlrikDie Gesamtvergütung ($USD209.02K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Swedish ($USD249.49K).

Entschädigung vs. Einkommen: UlrikDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Ulrik Harrysson (54 yo)

4.8yrs

Amtszeit

SEK 2,282,000

Vergütung

Mr. Ulrik Harrysson had been an Independent Director at Qlife Holding AB (publ) since may 5, 2021 until May 2023. He has been the Chief Executive Officer at SyntheticMR AB (publ) since July 1, 2019. He ser...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ulrik Harrysson	Chief Executive Officer	4.8yrs	SEK 2.28m	0.34% SEK 3.9m
Jan Bertus Warntjes	Head of Innovation	6.3yrs	keine Daten	8.3% SEK 95.8m
Johanna Noren	CFO & Head of Investor Relations	3yrs	keine Daten	0.0073% SEK 84.2k
Markus Malmgren	Chief Technology Officer	no data	keine Daten	keine Daten
Vedran Beglerbegovic	C.P.O	no data	keine Daten	0.010% SEK 115.8k

4.8yrs

Durchschnittliche Betriebszugehörigkeit

49yo

Durchschnittliches Alter

Erfahrenes Management: SYNTDas Führungsteam des Unternehmens gilt als erfahren (4.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Bertus Warntjes	Head of Innovation	17.3yrs	keine Daten	8.3% SEK 95.8m
Johan Sedihn	Chairman	13.3yrs	SEK 350.00k	4.66% SEK 53.8m
Staffan Persson	Director	11.3yrs	SEK 150.00k	29.31% SEK 338.5m
Ann-Christine Sundell	Director	3.3yrs	SEK 150.00k	0.012% SEK 138.5k
Petra Apell	Director	3.9yrs	SEK 150.00k	0.011% SEK 129.7k
Alex Rovira	Member of Medical Advisory Board	3.4yrs	keine Daten	keine Daten
Jeff Miller	Member of Medical Advisory Board	1.8yrs	keine Daten	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: SYNTDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

SyntheticMR Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

No independent directors

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

Recent updates

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

SyntheticMR AB (publ), Annual General Meeting, May 10, 2022

SyntheticMR AB (publ) to Report Q1, 2022 Results on May 10, 2022

Now 24% undervalued after recent price drop

Syntheticmr AB (Publ) Announces Net Sales Guidance for the First Quarter 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Third quarter 2021 earnings released: EPS kr0.06 (vs kr0.004 loss in 3Q 2020)

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyntheticMR Signs Global Agreement with Philips to include SyntheticMR's Solution in Third Party Product Catalogue

Second quarter 2021 earnings released

Consensus EPS estimates fall to kr0.32